Patient-Reported Outcomes in Infectious Keratitis: A Systematic Review.

CorneaAug 21, 2026 (epub)
Clinical ResearchOphthalmologyOpen access

James Smith, Christian P Pappas, Maria Cabrera-Aguas et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated patient-reported outcome measures (PROMs) used to assess quality of life (QoL) in patients with infectious keratitis. Eight studies were included, revealing that patients experienced impaired QoL across various domains, particularly in vision and visual function. Only 13% of the studies employed psychometric analysis to validate the PROMs.

Key findings

  • Patients with infectious keratitis showed impaired QoL across all PROMs evaluated.
  • Vision and visual function were the most affected domains in patients' QoL.
  • Only 1 out of 8 studies (13%) validated the PROMs using psychometric analysis.

Why it matters

Understanding the impact of infectious keratitis on patients' quality of life is crucial for clinicians to address the subjective experiences of their patients and improve healthcare delivery. Validated PROMs can enhance the assessment and management of this condition.

Source

PubMed · PMID 42474397Free full text on PubMed Central

Published in Cornea. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.